



Local Decisions on SMC Advice

The Tayside Area Formulary (TAF) is not a comprehensive list of all SMC approved medicines. Drugs which are rarely used, are too specialist for the local Formulary, or are used in the paediatric population will not be listed in the Formulary.

These specialist medicines can be found via the [Local Decisions on SMC Advice tab](#) which can be accessed via the TAF.

This tab links to an alphabetical list of all new medicines which have been reviewed by SMC (including those which are not recommended by SMC), the indication reviewed and the local NHS Board's decision(s).

[Standardised wording](#) introduced in 2016 for NHS Boards to use regarding the local decision on SMC advice means it is not always clear what the local decision is.

The standard wording does not state who is able to prescribe the drug. As of December 2018, specialist medicines in this tab will have more specific prescribing information included under the standard statement on the local advice section as follows:

- Hospital only (specify speciality)
- GP under the direction of hospital specialist (specify speciality and whether initial prescribing to be done in secondary care).

Examples of drugs which are not in the Formulary and will include this information are:

- Hydrocortisone 0.5mg, 1mg, 2mg and 5mg granules (SMC accepted with restrictions; for patients under 6 years of age only)
- Telotristat (GPs can prescribe under the direction of the neuroendocrine clinic).

SMC Advice

Published 8th October 2018

Anakinra 100mg/0.67mL solution for injection in pre-filled syringe (Kineret®) SMC2104

Gemtuzumab ozogamicin 5mg powder for concentrate for solution for infusion (Mylotarg®) SMC2089

Hydrocortisone 0.5mg, 1mg, 2mg and 5mg granules in capsules for opening (Alkindi®) SMC2088

Ipilimumab 5mg/mL concentrate for solution for infusion (Yervoy®) SMC2094

Ixekizumab 80mg solution for injection in pre-filled syringe or pen (Taltz®) SMC2097

SMC 'Not recommended' medicines - October 2018

Cabozantinib, 20mg, 40mg, and 60mg film-coated tablets (Cabometyx®) SMC2095

Cenegermin 20mg/ml eye drops, solution (Oxervate®) SMC2124

Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2125

Sirolimus 0.5mg, 1mg and 2mg coated tablets and 1mg/ml oral solution (Rapamune®) SMC2126

Published 12th November 2018

Dinutuximab beta 4.5mg/mL concentrate for solution for infusion (Qarziba®) SMC2105

Fosaprepitant 150mg powder for solution for infusion (Ivemend®) SMC2108

SMC 'Not recommended' medicines - November 2018

Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2103

Evolocumab 140mg solution for injection in pre-filled syringe / 140mg solution for injection in pre-filled pen / 420mg solution for injection in cartridge (Repatha®) SMC2133

Fampridine 10mg prolonged-release tablet (Fampyra®) SMC2107

Local implementation of SMC recommendations is taken forward by the Tayside Prescribing Support Unit (PSU). This bulletin is based on evidence available to Tayside PSU at time of publication and is covered by the Disclaimer and Terms & Conditions of Use.

Local processes exist to allow prescribing of non-SMC approved medicines for individual patients and are available in the [Policy on Prescribing of Non-Formulary Medicines \(including PACS Tier 1 & 2\)](#)



For full information on any of the drugs listed below use the link to the Scottish Medicines Consortium (SMC) website below to search by generic, brand or SMC no.
See NHS Tayside 'Local Decisions on SMC Advice' database (link below) for full details on Board decisions - these are currently listed alphabetically by page.

New & Updated Formulary Links

- [Hormonal Contraception: NHS Tayside Formulary, pharmacological content and other characteristics, advice from TSRHS, October 2018](#)
- [Rheumatoid arthritis in adults: management, July 2018](#)
- [Rheumatology GP letter \(methotrexate\)](#) (Staffnet intranet link)
- [Shared Care Agreement – Biologic Therapies for Rheumatic Disease](#) (Staffnet intranet link)
- [NHS Tayside Dermatology Department - Dimethyl fumarate \(Skilarence\) Monitoring sheet](#) (Staffnet intranet link)
- [Dapsone Shared Care Agreement](#) (Staffnet intranet link)

Other Formulary Updates

- Paravit-CF[®] (Vitamins A, D, E, K) – added to formulary (Amber traffic light) restricted to prescribing under the direction of the CF team for CF patients with pancreatic insufficiency
- [Obstetrics & Gynaecology specialist formulary list](#) updated in relation to Assisted Conception Unit (ACU) specialist medicines

Links to Additional Information

Monthly Drug Safety Updates:

www.gov.uk/government/publications/drug-safety-update-monthly-newsletter

For full details of medicines and forthcoming SMC Advice see SMC Website:

www.scottishmedicines.org.uk

For a Summary of a Product's Characteristics (SPCs) see Electronic Medicines Compendium Website:

<http://www.medicines.org.uk/emc/>

For full details on NHS Board decisions see Tayside Area Formulary - Local Decisions on SMC Advice database:

<http://www.nhstaysideadtc.scot.nhs.uk/approved/formular/NewMedsHomepage.htm>

Medicines within the Tayside Area Formulary are intended to guide choice on a rational selection of medicines for **adults** which have been included on the basis of clinical efficacy, safety, patient acceptability and cost-effectiveness.

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Area Drug and Therapeutics Committee. Please direct any queries to:

Hazel Steele, Lead Pharmacist, Prescribing Support
E-mail: hazelsteele@nhs.net

Claire James, Senior Pharmacist - Clinical Effectiveness
E-mail: clairejames@nhs.net

Karen Harkness, Principal Pharmacist, Clinical Effectiveness
E-mail: kharkness@nhs.net